Related Experiment Video
Updated: Oct 10, 2025
08:51
Profiling of Permethylated Mucin O-glycans Using Matrix-assisted Laser Desorption/Ionization Time-of-flight Mass Spectrometry
Published on: June 20, 2025
316
Bone Biomarkers in Mucopolysaccharidoses.
Akari Nakamura-Utsunomiya1,2,3
1Department of Pediatrics, Hiroshima Prefectural Hospital, 1-5-54 Ujina-Kanda, Minami-ku, Hiroshima 734-8551, Japan.
International Journal of Molecular Sciences
|December 10, 2021
Summary
Mucopolysaccharidoses (MPS) cause progressive bone and cartilage damage. New proteomic biomarkers offer hope for evaluating MPS bone disease and monitoring treatment effectiveness.
Area of Science:
- Biochemistry
- Orthopedics
- Genetics
Background:
- Glycosaminoglycan (GAG) accumulation in mucopolysaccharidoses (MPS) causes progressive cartilage damage and impaired bone growth.
- Pathophysiology involves chondrocyte dysfunction, failed endochondral ossification, and inflammatory cytokine release.
- Current treatments for MPS bone disorders are limited, highlighting a need for better monitoring tools.
Purpose of the Study:
- To review advances in understanding bone metabolism in MPS.
- To identify and summarize novel bone and cartilage biomarkers for MPS.
- To discuss the potential of these biomarkers in evaluating disease progression and treatment efficacy.
Main Methods:
- Literature review of studies on MPS pathophysiology and bone metabolism.
- Analysis of recent research utilizing proteomic and other advanced analytical methods.
- Synthesis of findings on identified biomarkers and their clinical relevance.
Main Results:
- GAG accumulation disrupts chondrocyte function and endochondral ossification.
- Inflammatory pathways, including Toll-like receptor activation, are implicated in MPS bone disease.
- Proteomic analysis has identified new potential biomarkers for MPS bone and cartilage.
Conclusions:
- Effective biomarkers are crucial for assessing MPS bone disease progression and treatment response.
- Advances in proteomic analysis are revealing novel biomarkers.
- Further research is needed to validate and implement these biomarkers in clinical practice for MPS patients.
Related Concept Videos
01:23Glycosaminoglycans
5.3K
Glycosaminoglycans (GAGs), also known as mucopolysaccharides, are long and linear polymers comprising of specific repeating disaccharides - the amino sugar that can be N-acetylglucosamine or N-acetylgalactosamine, and a uronic acid that is usually glucuronic acid or iduronic acid.
GAGS are found in the extracellular matrix of vertebrates, invertebrates, and bacteria. Due to their polar nature they attract water, and serve as excellent lubricants or shock absorbers in an animal body.
Hyaluronic...
GAGS are found in the extracellular matrix of vertebrates, invertebrates, and bacteria. Due to their polar nature they attract water, and serve as excellent lubricants or shock absorbers in an animal body.
Hyaluronic...
5.3K
01:05Proteoglycans
4.1K
Glycans, a class of complex heterogeneous molecules, can be covalently attached to proteins to form glycosylated proteins that regulate various physiological and pathological processes. Glycosylated proteins or glycoproteins comprise N-linked and O-linked oligosaccharides. O-glycosylation is the most common type of protein glycosylation. Here, glycans attach to the oxygen atom of the hydroxyl groups of Serine or Threonine residues. O-linked glycosylation occurs later in protein processing,...
4.1K
01:24Oligosaccharide Assembly
3.1K
Protein glycosylation starts in the ER lumen and continues in the Golgi apparatus. Glycosyltransferases catalyze the addition of sugar molecules or glycosylation of proteins. Usually, these enzymes add sugars to the hydroxyl groups of selected serine or threonine residues to form O-linked glycans or the amino groups of asparagine residues to form N-linked glycans. Different positions on the same polypeptide chain can contain differently linked glycans.
Multiple sugar molecules that may or may...
Multiple sugar molecules that may or may...
3.1K